AOD-9604 vs MK-677
A comprehensive, data-driven comparison of AOD-9604 (Advanced Obesity Drug) and MK-677 (Ibutamoren). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | AOD-9604 Advanced Obesity Drug, Tyr-hGH Fragment 176-191 | MK-677 Ibutamoren, Nutrobal |
|---|---|---|
| FDA Status | Phase 2 (failed; reclassification pending) | Phase 2 |
| Category | Weight Loss | Growth Hormone |
| Primary Use | Fat loss and metabolism enhancement | Growth hormone optimization and muscle growth |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $30 - $60/mo | $50 - $100/mo |
| Administration | Subcutaneous injection | Oral |
| Typical Dose | 300mcg daily | 10-25mg daily |
| Frequency | Daily | Daily |
| Mechanism | Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without affecting blood sugar or IGF-1 | Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Low | Moderate |
| Clinical Trial Phase | Phase 2 | Phase 2 |
Key Differences
- 1AOD-9604 is generally more affordable ($30 - $60/mo) compared to MK-677 ($50 - $100/mo).
- 2AOD-9604 is administered via subcutaneous injection, while MK-677 uses oral.
- 3MK-677 has moderate-quality evidence, while AOD-9604 has low-quality evidence.
- 4They belong to different categories: AOD-9604 (Weight Loss) vs MK-677 (Growth Hormone).
Which Is Better For...
AOD-9604
More budget-friendly option with lower monthly costs
AOD-9604
Fewer commonly reported side effects
MK-677
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| AOD-9604 | $30 - $60/mo | Phase 2 (failed; reclassification pending) | Various research labs |
| MK-677 | $50 - $100/mo | Phase 2 | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
AOD-9604 works via Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis. MK-677 works via Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1. They differ in FDA approval status, efficacy data, and cost.
AOD-9604 typically costs $30 - $60/mo, while MK-677 costs $50 - $100/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
AOD-9604 is not FDA-approved (Phase 2 (failed; reclassification pending)). MK-677 is not FDA-approved (Phase 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of AOD-9604 include Injection site reactions, Headache, Chest tightness (rare). Common side effects of MK-677 include Increased appetite, Water retention, Fatigue. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
AOD-9604 is a modified peptide fragment of the C-terminus of human growth hormone (amino acids 176-191). It was designed to retain the fat-burning properties of HGH while avoiding effects on blood sug...
View Full AOD-9604 GuideMK-677 (Ibutamoren) is an orally-active growth hormone secretagogue that mimics the action of ghrelin. Unlike peptide injections, it is taken orally and has a long half-life allowing once-daily dosing...
View Full MK-677 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between AOD-9604 and MK-677 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.